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“Common active comorbid medical conditions among mental health users treated by the 
Assertive Community Treatment Team at Valkenberg Psychiatric Hospital” 
 
Abstract 
Introduction 
People with severe mental illness have co-morbid medical conditions which are often undiagnosed and 
untreated leading to morbidity and mortality. 
Aims and Objectives  
The aim of this study was to investigate the documented rate of comorbid medical conditions in the 
Valkenberg Hospital Assertive Community Treatment (ACT) service population. The objectives were to 
determine the rate and type of comorbid medical conditions documented at the community clinic and to 
compare these findings with data recorded in the ACT services files. Analysis was undertaken to determine 
whether there was an association between the clinical measures and socio-demographic findings.  
Methods 
A descriptive, analytical, retrospective folder review was conducted on the ACT population of Valkenberg 
hospital. All clients treated by the ACT team between the 1st of January 2015 and the 31st of December 2015 
were included in the study. The data was collected using a questionnaire.  
Results 
The ACT team treated 104 patients during the time of the study period. The age range was 21 to 63 years old 
(median 46). Thirty six of the patients were female (34.6%), sixty-eight (65.4%) were male. Substance use was 
documented in ninety-one (n=91) (87.5%) of all cases. Smoking was documented in sixty five (62.5%) of   
patients. Of the entire study sample, fifty-three patients (50.9%) had at least one medical condition. The most 
common active medical conditions documented at the patients’ combined treatment facilities were 
medication side-effects (22.3%), hypercholesterolemia (18.1%) and hypertension (10.6%). Significantly more 
medical conditions were recorded at Valkenberg hospital compared to the community clinics. There was an 
increase in metabolic illnesses in the middle age (44-53 years) group. Hypertension, diabetes mellitus and HIV 
appear to be slightly more common in females compared to males in this population. 
Discussion 
The study found comparatively low rates of medical conditions among the patients managed by the ACT team 
of Valkenberg hospital and the community clinics. These findings are not consistent with reviewed literature 
that found high rates of chronic medical conditions among people with severe mental illness. The rate of co-
morbid medical conditions is likely to be underestimated as they were not routinely screened for at both 
Valkenberg hospital and the community health centres.   
Conclusion 
The study highlights a gap between the management of mental illness and medical conditions in the ACT 
population. This has implication for the service provision of these clients in future. 
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Chapter 1: Introduction and literature review 
Severe mental illness and its associations with chronic health conditions 
 
People with severe mental illness (SMI) often have comorbid health problems which are 
undiagnosed and untreated, leading to morbidity and mortality (1). Severe mental illness is defined 
here as the presence of a major psychiatric disorder such as schizophrenia or bipolar disorder and 
that tends to be chronic. It causes significant social and occupational dysfunction (2, 3).  People with 
SMI have increased rates of physical illness compared to the general population (4, 5).  They also 
have a reduced life expectancy (6). According to Parks et al., people with SMI die an average of 25 
years sooner than those in the general population (6). Most of the causes of mortality are due to 
physical illness (5, 6).  
 
The physical health of people with schizophrenia has been a neglected area of psychiatry and 
general medicine (7). In keeping with other severe mental illnesses, people living with schizophrenia 
have more co-morbid physical illnesses than the general population (5). According to Salokangas, it 
is estimated that people with schizophrenia have at least one chronic co-morbid medical condition 
(7). These conditions include obesity, diabetes mellitus, hyperlipidaemia, cardiovascular disease, 
human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), hepatitis and 
malignancies. Casey  documented a 1.6-fold increase in mortality in people with schizophrenia, 
leading to a 20% lower life expectancy compared to the general population (5, 8). Other 
investigators estimated that mortality in this group is 2-3 times higher than in the general population 
(8, 9). Similar findings have been reported for other SMIs, including bipolar disorder (8).   
 
Chronic medical conditions and metabolic syndrome in people with severe mental illness 
 
Increased morbidity and mortality in people with SMI is mostly due to treatable medical conditions 
caused by preventable and modifiable risk factors such as smoking, substance use, obesity and 
inadequate access to medical care (6). Sixty percent  of premature deaths in people with 
schizophrenia are due to medical conditions that include cardiovascular disease, pulmonary disease 
and infectious diseases(6). Also amongst the causes of early death in people with SMI is metabolic 
syndrome, which is exacerbated  by the increased use of second generation antipsychotics (6).  
 
Metabolic syndrome was defined by the International Diabetic Federation in 2005 as an increased 
waist circumference with at least two other health abnormalities, which could be hypertension, low 
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high density lipoprotein (HDL), or raised fasting blood glucose or triglycerides (10, 11). It is known 
that the presence of metabolic syndrome increases morbidity and mortality due to cardiovascular 
disease (12, 13). People with schizophrenia are often overweight or obese, defined as a Body Mass 
Index (BMI) equal to, or greater than 30. A BMI of 25 – 29.9 is considered overweight. According to 
Castillo et al., it is recognized that patients on a community outreach Assertive Community 
Treatment (ACT)  programme have high rates of potentially unrecognized cardio-metabolic illnesses 
(14). In addition, Sub Saharan Africa has the largest increase in prevalence of Type 2 diabetes 
mellitus and cardiovascular disease globally (15). 
 
People with SMI are also at significant  risk of HIV infection. According to Joska et al., the prevalence 
of HIV infection continues to rise in Sub Saharan Africa. It  may therefore be assumed that the 
increase in prevalence in HIV in the general South African population would be is associated with an 
increase in the rate of in HIV in patients with SMI (2). 
 
Risk factors for increased morbidity and mortality in people with severe mental illness. 
 
Factors for increased morbidity and mortality in people with severe mental illness are numerous, 
complex and multifactorial.  According to Robson et al., the reasons for poor physical health in this 
population are divided into service-related factors, illness-related factors, treatment related factors 
and health behaviours (4).  
 
Service related factors include difficulty accessing outpatient primary care services, lack of 
preventative health care and a lack of clarity about whose role it is to manage physical illnesses in 
patients with severe mental illness.  
 
Illness related factors include decreased help seeking behaviour, cognitive deficits, and negative 
symptoms which forms part of the symptom profile of schizophrenia. Severe mental illness affects 
education, employment status, social and family support and is often associated with stigma. People 
with severe mental illness are often unemployed and living in poverty (4). This in turn plays a role in 
accessing primary health care services.  
 
High risk behaviours like smoking and substance use, physical inactivity and poor diet are some of 
the patient related factors contributing to poor physical health in people with SMI.  Studies have 
shown that the rate of tobacco smoking in people with SMI is up to three times higher than the 
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general population (4). Of all SMI, smoking prevalence is highest in patients with schizophrenia (16). 
The literature describes numerous reasons for this which includes smoking being used to attenuate 
the side effects related to dopamine blockade of antipsychotic drugs and self-medication of negative 
symptoms of schizophrenia(4).  
 
Treatment related factors include the metabolic side effects of certain psychotropic medication 
contributing to ill physical health (4, 17).  
 
Physical health care needs of patients with SMI often go unmet for the aforementioned reasons (17, 
18). 
 
Screening and monitoring for medical illness in people with severe mental illness.   
 
A review of the association between SMI, metabolic syndrome, diabetes mellitus and antipsychotic 
drugs concludes that there is a need for routine physical health screening in patients with severe 
mental illness taking antipsychotics (10). There are multiple guidelines that describe the rationale 
and protocols for screening as mentioned below.  
 
According to The Maudsley Prescribing Guidelines in Psychiatry (19), people taking antipsychotic 
drugs should have their weight, blood lipids plasma glucose  monitored at baseline then at three to 
six months then every six months to detect antipsychotic induced changes. The Maudsley guidelines 
also recommend the monitoring of the patient’s blood pressure at baseline and during dose titration 
to detect antipsychotic induced changes and doing an echocardiogram at baseline prior to starting 
the antipsychotic medication. 
 
Saloojee, et al refers to the 2005 South African guideline for the management of metabolic 
abnormalities in people with schizophrenia which recommends plasma glucose and lipids and blood 
pressure monitoring prior to initiation of second generation antipsychotic medication, then at six 
weeks, four months and twelve months and annually thereafter (12).  
 
Metabolic screening practices are also shown to be inadequate in high income countries (12). Barnes 
et al. did an audit of clinical records of patients under the care of eight Assertive Outreach teams 
across the United Kingdom (20). They examined the screening of metabolic side effects of 
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antipsychotic medications in community patients. They found that the rates of screening were well 
below what has been recommended. 
 
Saloojee et al. conducted a study on 331 outpatients with severe mental illness on antipsychotic 
medication for six months in Durban, South Africa, and examined  metabolic testing in these clients 
in the previous year (12).  Only 2patients (0.6%) in this study were screened for all five components 
of metabolic syndrome (12).  
 
In a further study, De Hert et al. noted that clinician screening practices in populations with mental 
health conditions  have consistently been suboptimal (21).The authors reported a systematic review 
of clinical practice guidelines for screening and monitoring of cardio-metabolic risk in patients with 
schizophrenia and summarised recommendations from 10 of 18 reviewed guidelines. Their 
recommendation included a baseline assessment followed by re-assessment after 3-4 months of 
initiation of treatment with an antipsychotic drug. The assessment measurements recommended 
include fasting glucose, triglycerides, cholesterol, and body mass index, high density lipoprotein to 
low density protein ratio (HDL/LDL), blood pressure and symptoms of diabetes mellitus. The authors 
also advised that all individuals with schizophrenia should be under active medical care and have 
screening of metabolic conditions at least annually. These recommendations are in agreement with 
the National Institute for Health and Clinical Excellence guidelines (22).   
 
The Assertive Community Treatment model 
 
The Assertive Community Treatment (ACT) model of care was developed by Stein et al. in the United 
States of America (USA)  in the 1970s (23) and it has been extensively researched. .  (23).  The 
original ACT model has been modified over time but the core features remain the same.  According 
to Bond, ACT is an intensive, recovery orientated, multidisciplinary, evidence-based outpatient 
treatment program for people with severe mental illness. There is a small staff member to consumer 
ratio (10 patients per 1 staff member), 24 hour staff availability, shared caseloads and daily team 
meetings. The ACT service aims to assist people with severe mental illness to integrate in the 
community. It uses a team approach of various mental health professionals. ACT contacts occur in 
the community. The ACT team aims to assist clients with medication, housing, finance and other 
issues needed for successful community living. Evidence shows ACT is successful in keeping clients 
engaged in mental health services, reduces the need for admission to psychiatric hospitals and it 
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improves symptoms and subjective quality of life (23). There are assertive outreach teams in many 
countries including the United Kingdom, Australia and the USA. 
 
The Assertive Community Treatment model in South Africa 
 
In January 2007 the Government Department of Health in the Western Cape province appointed 
three community treatment teams at Stikland, Valkenberg and Lentegeur Hospitals (24). The 
Assertive Community Treatment model was introduced to these regional psychiatric hospitals in an 
attempt to reduce hospital readmissions amongst high frequency users sometimes called “revolving 
door patients” (25). The “revolving door patient” is the term used for individuals with frequent 
admissions to the psychiatric hospitals with short periods of remaining well outside of hospital (24). 
According to Botha et al., the international ACT model of care is not feasible or cost-effective in 
South Africa. Provision of community based care depends on community resources which are limited 
in South Africa.  Thus, the international high income country ACT model was modified and 
introduced to the Western Cape Province to provide for higher caseloads and less frequent patient-
service contacts than in higher resourced settings. The multidisciplinary team in the South African 
ACT model consists of a psychiatrist, social worker and psychiatric nurse. Caseloads are shared. The 
service model identified in 2007 was as follows: (15).  
• Patients deemed suitable for the service were identified on admission to the psychiatric 
hospital using a modified version of Weiden’s criteria (24). 
• The patient and his/her family were introduced to the service whilst the patient is still in 
hospital. 
• Once patients are discharged from hospital they are actively followed up by the team. 
• Contact between home visits is maintained by telephone calls with family members. 
• Should patients relapse and require admission, they bypass community services and are 
admitted directly to the psychiatric facility. 
 
The majority of the ‘revolving door’ patients live in adverse social circumstance (24). Most of them 
are unemployed and dependent on a government grant. Some of them live in informal settlements 
and have chaotic environments, food insufficiency, overcrowding and is faced with gang violence on 
a daily basis. All this impacts on their illness and their ability to be adherent to medication and 
attend community clinics (24). The clinics are often understaffed with long waiting times before 
seeing health care providers and long waiting times at the pharmacy. These factors also influence 
patients’ ability to adhere to clinic appointments (24). Botha et al. concluded that the ACT 
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intervention proved effective in reducing psychiatric hospital admissions and improving clinical 
outcomes. 
 
Observations from the Assertive Community Treatment (ACT) service of Valkenberg Hospital 
 
Valkenberg Hospital is one of four dedicated Psychiatry and Mental Health Hospitals in the Western 
Cape. It offers a general psychiatric and mental health service to the Cape Town Metro Region as 
well as a specialised forensic service. The Valkenberg Hospital catchment area includes the Metro 
Southern suburbs, South Peninsula, parts of the Cape flats, including Langa, Lotus River, Manenberg, 
Gugulethu, Lavender Hill, Heideveld, Grassy Park and Atlantis. The ACT team is based at Valkenberg 
Hospital and services clients living in community settings. The primary aim of the ACT service is to 
decrease recurrent readmissions to Valkenberg Hospital and to assist clients to live productive lives 
in their communities. This is achieved through regular assertive contacts with the patient and his or 
her carer in the community with emphasis on holistic care and recovery. 
 
The essential features of the international ACT model remain the same in the Valkenberg Hospital 
service. The ACT team has a case load of approximately one hundred clients per month. The 
Multidisciplinary treatment team (MDT) consists of a psychiatrist, a medical officer, two professional 
nurses and two social workers. Each client has contact with all the members of the MDT as per need. 
The locus of contact is in the client’s own community. The ACT team does daily home visits and sees 
between eight to ten clients per day. A mental state examination is done by a staff member and 
psychotropic medication including long acting injectable antipsychotics are provided to the client at 
his or her home. Clients are seen on average between two to four weekly intervals depending on 
their clinical condition and the frequency of the long acting injectable antipsychotics. Should a client 
be mentally unwell he/she is seen more frequently sometimes up to twice weekly. If a client requires 
admission to a psychiatric hospital the ACT team admits the client directly from the community to 
Valkenberg Hospital. If a client is an inpatient at Valkenberg Hospital, both the medical and 
psychiatric care is provided by the medical officer and the psychiatrist of the ACT team. When clients 
with a co-morbid illness are discharged from Valkenberg Hospital, they are referred to the 
community health centre in their area.  
 
 According to the currently practiced model of care, clients on the Valkenberg Hospital ACT program 
do not receive integrated health care and they are required to attend their local community health 
clinic for treatment and medication for any general medical conditions. 
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The above model of care differs from some of the international ACT models that may use a more 
integrated approach to caring for the physical and mental health care needs of their clients (8). 
Routine screening for cardiometabolic illnesses and other illnesses like HIV are therefore not 
undertaken in the local setting. 
 
Aim of the study 
 
To investigate the documented occurrence of comorbid medical conditions in the Valkenberg 
Hospital ACT service population. 
 
Objectives 
1. To determine the rate and type of co-morbid medical conditions documented in the folders 
of patients on the assertive community treatment program and at local community health 
centre 
 
2. To determine if there is an association between the clinical variables and socio-
demographic profile in the study population. 
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Abstract 
Introduction 
People with severe mental illness have co-morbid medical conditions which are often undiagnosed and 
untreated leading to morbidity and mortality. 
Aims and Objectives  
The aim of this study was to investigate the documented rate of comorbid medical conditions in the 
Valkenberg Hospital Assertive Community Treatment (ACT) service population. The objectives were to 
determine the rate and type of comorbid medical conditions documented at the community clinic and to 
compare these findings with data recorded in the ACT services files. Analysis was undertaken to determine 
whether there was an association between the clinical measures and socio-demographic findings  
Methods 
A descriptive, analytical, retrospective folder review was conducted on the ACT population of Valkenberg 
hospital. All clients treated by the ACT team between the 1st of January 2015 and the 31st of December 2015 
were included in the study. The data was collected using a questionnaire.  
Results 
The ACT team treated 104 patients during the time of the study period. The age range was 21 to 63 years old 
(median 46). Thirty six of the patients were female (34.6%), sixty-eight (65.4%) were male. Substance use was 
documented in ninety-one (n=91) (87.5%) of all cases. Smoking was documented in sixty five (62.5%) of   
patients. Of the entire study sample, fifty-three patients (50.9%) had at least one medical condition. The most 
common active medical conditions documented at the patients’ combined treatment facilities were 
medication side-effects (22.3%), hypercholesterolaemia (18.1%) and hypertension (10.6%). Significantly more 
medical conditions were recorded at Valkenberg hospital compared to the community clinics. There was an 
increase in metabolic illnesses in the middle age (44-53 years) group. Hypertension, diabetes mellitus and HIV 
appear to be slightly more common in females compared to males in this population. 
Discussion 
The study found comparatively low rates of medical conditions among the patients managed by the ACT team 
of Valkenberg hospital and the community clinics. These findings are not consistent with reviewed literature 
that found high rates of chronic medical conditions among people with severe mental illness. The rate of co-
morbid medical conditions is likely to be underestimated as they were not routinely screened for at both 
Valkenberg hospital and the community health centres.   
Conclusion 
The study highlights a gap between the management of mental illness and medical conditions in the ACT 
population. This has implication for the service provision of these clients in future. 
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BACKGROUND 
 
People with severe mental illness (SMI) often have comorbid health problems which are 
undiagnosed and untreated, leading to morbidity and mortality(1). Severe mental illness is defined 
here as the presence of a major psychiatric disorder such as schizophrenia or bipolar disorder and 
that tends to be chronic. It causes significant social and occupational dysfunction (2, 3).  People with 
SMI have increased rates of physical illness compared to the general population (4, 5).  They also 
have a reduced life expectancy(6). According to Parks et al., people with SMI die an average of 25 
years sooner than those in the general population (6). Most of the causes of mortality are due to 
physical illness (5, 6).  
 
The physical health of people living with schizophrenia has been a neglected area of psychiatry and 
general medicine(7). In keeping with other severe mental illnesses, people with schizophrenia have 
more co-morbid physical illnesses than the general population (5). According to Salokangas, it is 
estimated that people with schizophrenia have at least one chronic co-morbid medical condition (7). 
These conditions include obesity, diabetes mellitus, hyperlipidaemia, cardiovascular disease, human 
immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), hepatitis and 
malignancies. Casey documented a 1.6-fold increase in mortality in people with schizophrenia, 
leading to a 20% lower life expectancy compared to the general population (5, 8). Other 
investigators estimated that mortality in this group is 2-3 times higher than in the general 
population(8, 9). Similar findings have been reported for other SMIs, including bipolar disorder(8).   
 
Increased morbidity and mortality in people with SMI is mostly due to treatable medical conditions 
caused by preventable and modifiable risk factors such as smoking, substance use, obesity and 
inadequate access to medical care(6). Sixty percent  of premature deaths in people with 
schizophrenia are due to medical conditions that include cardiovascular disease, pulmonary disease 
and infectious diseases(6). Also amongst the causes of early death in people with SMI is metabolic 
syndrome, which is exacerbated  by the increased use of second generation antipsychotic 
medications (6).  
 
Metabolic syndrome was defined by the International Diabetic Federation in 2005 as an increased 
waist circumference with at least two other health abnormalities, which could be hypertension, low 
high density lipoprotein (HDL), or raised fasting blood glucose or triglycerides (10, 11). It is known 
that the presence of metabolic syndrome increases morbidity and mortality due to cardiovascular 
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disease (12, 13). People with schizophrenia are often overweight or obese, defined as a Body Mass 
Index (BMI) equal to, or greater than 30 (26). A BMI of 25 – 29.9 is considered overweight. Castillo et 
al., recognized that patients on a community outreach ACT programme have high rates of potentially 
unrecognized cardio-metabolic illnesses (14). In addition, Sub Saharan Africa has the largest increase 
in prevalence of Type 2 diabetes mellitus and cardiovascular disease globally (15). 
 
 People with SMI are also at significant risk of HIV infection. According to Joska et al., the prevalence 
of HIV infection continues to rise in Sub Saharan Africa. It  may therefore be assumed that the 
increase in prevalence in HIV in the general South African population would be is associated with an 
increase in HIV in patients with SMI (2).  
 
Risk factors for increased morbidity and mortality in people with severe mental illness are 
numerous, complex and multifactorial.  According to Robson et al., the reasons for poor physical 
health in this population are divided into service-related factors, illness-related factors, treatment 
related factors and health behaviours (4).  
 
Service related factors include difficulty accessing outpatient primary care services, lack of 
preventative health care and a lack of clarity about whose role it is to manage physical illnesses in 
patients with severe mental illness (4). Illness related factors include decreased help seeking 
behaviour, cognitive deficits, and negative symptoms which forms part of the symptom profile of 
schizophrenia. Severe mental illness affects education, employment status, social and family support 
and is often associated with stigma. People with severe mental illness are often unemployed and 
living in poverty (4). This in turn plays a role in accessing health care services. High risk behaviours 
such as smoking and substance use, physical inactivity and poor diet are some of the patient related 
factors contributing to poor physical health in people with SMI (26).  Studies have shown that the 
rate of smoking in people with SMI is up to three times higher than the general population (4, 27). Of 
all SMI, smoking prevalence is highest in patients with schizophrenia (16). The literature describes 
numerous reasons for this which include smoking being used to attenuate the side effects related to 
dopamine blockade of antipsychotic drugs and self-medication of negative symptoms of 
schizophrenia(4). Treatment related factors include the metabolic side effects of certain 
psychotropic medication contributing to ill physical health (4, 17). Physical health care needs of 
patients with SMI often go unmet for the aforementioned reasons (17, 18). 
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A review of the association between SMI, metabolic syndrome, diabetes mellitus and antipsychotic 
drugs concludes that there is a need for routine physical health screening in patients with SMI who 
are prescribed antipsychotic medication (10). There are multiple guidelines that describe the 
rationale and protocols for screening as outlined below.  
 
According to The Maudsley Prescribing Guidelines in Psychiatry,  (19), people taking antipsychotic 
drugs should have their weight, blood lipids plasma glucose  monitored at baseline then at three to 
six months then every six months to detect antipsychotic drug induced changes. The Maudsley 
guidelines also recommend the monitoring of the patient’s blood pressure at baseline and 
“frequently” during dose titration to detect antipsychotic induced changes and doing an 
echocardiogram at baseline prior to starting the antipsychotic medication. 
 
Saloojee, et al refers to the 2005 South African guideline for the management of metabolic 
abnormalities in people with schizophrenia which recommends plasma glucose and lipids and blood 
pressure monitoring prior to initiation of second generation antipsychotic medication, then at six 
weeks, four months and twelve months and annually thereafter (12).  
 
Metabolic screening practices in patients with severe mental illness are documented to be 
inadequate in high income countries (12). Barnes et al. undertook an audit of clinical records of 
patients under the care of eight Assertive Outreach teams across the United Kingdom (20). They 
examined screening of metabolic side effects of antipsychotic medications in community based 
patients and found that rates of screening were well below what has been recommended.   
 
Saloojee et al. conducted a study on 331 outpatients with severe mental illness on antipsychotic 
medication for six months in Durban, South Africa, and documented  metabolic testing in these 
clients in the previous year (12). They reported that in spite of Sub Saharan Africa having the largest 
increase in prevalence of Type 2 diabetes mellitus and cardiovascular disease globally, only 2 
patients in this study (0.6% of the sample) were screened for all five components of metabolic 
syndrome.  
 
In a further study, De Hert et al. noted that clinician screening practices in populations with mental 
health conditions  have consistently been suboptimal (21). The authors reported a systematic review 
of clinical practice guidelines for screening and monitoring of cardiometabolic risk in patients with 
schizophrenia and summarised recommendations from 10 of 18 reviewed guidelines. Their 
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recommendation included a baseline assessment followed by re-assessment after 3-4 months of 
initiation of treatment with an antipsychotic drug. The assessment measurements recommended 
include fasting glucose, triglycerides, cholesterol, body mass index, high density lipoprotein to low 
density protein ratio (HDL/LDL), blood pressure and symptoms of diabetes mellitus. The authors also 
advised that all individuals with schizophrenia should be under active medical care and have 
screening of metabolic conditions at least annually. These recommendations are in agreement with 
the National Institute for Health and Clinical Excellence guidelines (22).   
 
The Assertive Community Treatment (ACT) model of care was developed by Stein et al. in the United 
States of America (USA)  in the 1970s (23) and it has been extensively researched. . The original ACT 
model has been modified over time but the core features remain the same.  According to Bond, ACT 
is an intensive, recovery orientated, multidisciplinary, evidence-based outpatient treatment 
programme for people with SMI. There is a small staff member to consumer ratio (10 patients per 1 
staff member), 24 hour staff availability, shared caseloads and daily team meetings. The ACT service 
aims to assist people with SMI to integrate into their living community. It uses a team approach of 
various mental health professionals. ACT contacts occur in community based settings. The ACT team 
aims to assist clients with medication, housing, finance and other issues needed for successful 
community living. Evidence shows ACT is successful in keeping clients engaged in mental health 
services, reduces the need for admission to psychiatric hospitals and it improves symptoms and 
subjective quality of life (23). There are assertive outreach teams in many countries including the 
United Kingdom, Australia and the USA. 
 
In January 2007 the Western Cape Province Government Department of Health appointed three 
community treatment teams at Stikland, Valkenberg and Lentegeur Hospitals (24). The Assertive 
Community Treatment model was introduced to these regional psychiatric hospitals in an attempt to 
reduce hospital readmissions amongst high frequency users sometimes called “revolving door 
patients” (25). The “revolving door patient” is the term used for individuals with frequent admissions 
to the psychiatric hospitals with short periods of remaining well outside of hospital (24). According 
to Botha et al., the international ACT model of care is not feasible or cost-effective in South Africa. 
Provision of community based care depends on community resources which are limited in South 
Africa.  Thus, the international high income country ACT model was modified and introduced to the 
Western Cape Province to provide for higher caseloads and less frequent patient-service contacts 
than in higher resourced settings. The multidisciplinary team in the South African ACT model consists 
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of a psychiatrist, social worker and psychiatric nurse. Caseloads are shared. The service model 
identified in 2007 was as follows: (15).  
• Patients deemed suitable for the service are identified on admission to the psychiatric 
hospital using a modified version of Weiden’s criteria (24). 
• The patient and his/her family are introduced to the service whilst the patient is still in 
hospital. 
• Once patients are discharged from hospital they are actively followed up by the team. 
• Contact between home visits is maintained by telephone calls with family members. 
• Should patients relapse and require admission, they bypass community services and are 
admitted directly to the psychiatric facility. 
 
The majority of the ‘revolving door’ patients live in adverse social circumstances (24). Most of them 
are unemployed and dependent on a government social grant. Some of them live in informal 
settlements and have chaotic environments, food insufficiency, overcrowding and are faced with 
gang and other community violence on a daily basis. All this impacts on their illness and their ability 
to be adherent to medication and attend community clinics (24). The clinics are often understaffed 
with long waiting times before seeing health care providers and long waiting times at the pharmacy. 
These factors also influence patients’ ability to adhere to clinic appointments (24). Botha et al. 
concluded that the ACT intervention proved effective in reducing psychiatric hospital admissions and 
improving clinical outcomes. 
 
Valkenberg Hospital is one of four dedicated Psychiatry and Mental Health Hospitals in the Western 
Cape. It offers a general psychiatric and mental health service to the Cape Town Metro Region as 
well as a specialised forensic service. The Valkenberg Hospital catchment area includes the Metro 
Southern suburbs, South Peninsula, parts of the Cape flats, including Langa, Lotus River, Manenberg, 
Gugulethu, Lavender Hill, Heideveld, Grassy Park and Atlantis. The ACT team is based at Valkenberg 
Hospital and services clients living in community settings. The primary aim of the ACT service is to 
decrease recurrent readmissions to Valkenberg Hospital and to assist clients to live productive lives 
in their communities. This is achieved through regular assertive contacts with the client and his or 
her carer in the community with emphasis on holistic care and recovery. 
 
 
The essential features of the international ACT model remain the same in the Valkenberg Hospital 
service. The ACT team has a case load of approximately one hundred clients with SMI per month. 
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The multidisciplinary treatment team (MDT) consists of a psychiatrist, a medical officer, two 
professional nurses and two social workers. Each client has contact with all the members of the MDT 
as per need. The locus of contact is in the client’s own community. The ACT team does daily home 
visits and sees between eight to ten clients per day. A mental state examination is done by a staff 
member and psychotropic medication including long acting injectable antipsychotics are provided to 
the client at his or her home. Clients are seen on average between two to four weekly intervals 
depending on their clinical condition and the frequency of the long acting injectable antipsychotics. 
Should a client be mentally unwell he/she is seen more frequently sometimes up to twice weekly. If 
a client requires admission to a psychiatric hospital the ACT team admits the client directly from the 
community to Valkenberg Hospital. If a client is an inpatient at Valkenberg Hospital, both the 
medical and psychiatric care is provided by the medical officer and the psychiatrist of the ACT team. 
When clients with a co-morbid illness are discharged from Valkenberg Hospital, they are referred to 
the community health centre in their area.  
 
 As determined by the currently practiced provincial model of care, clients on the specialist 
Valkenberg Hospital ACT program do not receive integrated health care and they are required to 
attend their local community primary health clinic for treatment and medication for any general 
medical conditions. Routine screening for cardiometabolic illnesses and other illnesses such as HIV 
are therefore not undertaken in the community setting. This model of care differs from some of the 
international ACT models that may use a more integrated approach to caring for the physical and 
mental health care needs of their clients (8).  
 
Aim of the study 
 
To investigate the documented occurrence of comorbid medical conditions in the Valkenberg 
Hospital ACT clients. 
 
Objectives 
1. To determine the rate and type of co-morbid medical conditions documented in the folders 
of clients on the assertive community treatment program and at their local community health 
centre. 
2. To determine if there is an association between the clinical variables and socio-demographic 
profile in the study population. 
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Methods 
Study setting and procedures 
The study conducted was a descriptive, analytical, retrospective folder review. The main study site 
was Valkenberg Hospital and included the community clinics in its designated catchment area where 
the ACT clients are expected to receive medical care.  
 
Community health centres (CHCs) and clinics included in the study were Hanover Park CHC, Retreat 
CHC, Grassy Park CHC, Vanguard CHC, Lotus River CHC Dr Abdurahman Clinic, Green Point Clinic and 
Lady Michaelis Clinics. Clinics in two health districts, Atlantis and Fish Hoek, were not included in the 
study as they are situated further from the study site than other participating clinic sites and were 
not easily accessible within the scope of this study. The following health facilities were excluded 
from the study as the researcher was not granted approval by the facility to access client folders: 
Heideveld CHC, Robbie Nurock Clinic, Woodstock CHC and Albouw Gardens Clinic. 
 
All clients who met the ACT service criteria and were treated by the ACT team between the 1st of 
January 2015 and the 31st of December 2015 were included in the study. The sample size was 104 
clients. Data were collected by the primary investigator. 
 
Data source 
The study data were obtained from clients’ current inpatient Valkenberg Hospital folder, the 
Valkenberg ACT service folders, Clinicom which is the hospital electronic discharge record, and the 
clients’ community health facility folder.  
 
Measures 
Only data recorded in the year of the study (2015) was included. 
The data collected comprised clinical and socio-demographic data. A questionnaire (see Appendix) 
was used to collect the data. The socio-demographic data included age, gender, marital status, 
highest level of education, current employment status (full-time, part time, unemployed) and 
whether a client receives a state disability grant. The local community clinic that the patient should 
attend for general health care was recorded as well as the date that the patient joined the ACT 
service. 
Clinical data included the primary psychiatric diagnosis, comorbid substance use disorder (cannabis, 
methaqualone, methamphetamine, other) and details of psychotropic medication prescribed, 
including first and second generation antipsychotics, mood stabilisers and antidepressants. 
The primary clinical outcome measure of interest for the study was the documented prevalence of 
co-occurring medical conditions which were categorised according to non-communicable diseases 
such as diabetes mellitus, hypertension, chronic obstructive pulmonary disease, 
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hypercholesterolaemia and communicable diseases such as HIV. Records of community clinic 
attendance and treatment of medical conditions that were documented in the community clinic and 
the ACT folders were noted for comparison. Tobacco smoking status and body mass index (BMI) 
were recorded as they are risks for cardiometabolic illness. Formal screening or testing of clients for 
co-occurring risk conditions was recorded.  
 
Ethical considerations 
Approval for the study was granted by the University of Cape Town Faculty of Health Sciences 
Human Research Ethics Committee (see Appendix, page 41). Approval to conduct the research at 
Valkenberg Hospital and Community Health Centres and Clinics was obtained from the Western 
Cape Government Department of Health, Valkenberg Hospital and the Cape Town Metro District 
Health Authority (see Appendix, page 42 to 46). 
 
Data analysis 
The clinical and socio-demographic data collected for each client were categorised and coded for 
analysis. Descriptive statistics were derived following analysis using IBM Statistical Package for Social 
Sciences (SPSS) version 22. Data comprising categorical variables were summarised as frequencies or 
percentages. The co-occurrence of documented medical conditions was expressed as a rate for the 
study population. Numerical data was described in terms of means for normally distributed data and 
medians for non-parametric data. Means and medians were compared using student t and Pearson 
Chi-Square tests as appropriate. The 95% confidence interval was the p-value and statistical 
significance was defined as a p-value of less than 0.05.   Associations of clinical and demographic 
measures were calculated using Pearson’s Chi-Square tests of association.   
 
Results 
The ACT team treated 104 clients during the study period. The ages were divided into three age 
bands. The age range was 21 to 63 years old (median 46); (Table 1). Thirty six of the clients were 
female (34.6%) and sixty-eight (65.4%) were male (Table 1).  
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Table 1: Summary of age groups and sex of clients in study (n=104) 
 
  Age 18-
29yrs. 
Age 30-
49yrs  
 Age 50-63 
yrs. 
Missing 
data 
 Total  Median Age 
range 
(yrs.) 
Males 13 36 18 1 68 42 23-62 
Females 2 14 18 2 36 50 21-63 
Total  15 50 36 3 104   
 
 
Information on marital status was not available for eleven (10.6%) clients. Of the cases (n=93) for 
which the marital status was known, eighty-five (91.4%) of the clients were single, three (3.2%) were 
married and five (5.4%) were separated/divorced.  
 In forty cases (38.5%) the highest level of education was not documented. Of those 64 cases 
documented, 57.7% had either primary or secondary school education. (see table 2).  
 
Table 2: Highest level of education within the ACT population (n=64) 
 
          Highest educational level 
 
    
 Count 
 
 
               Percent % 
Primary school (less than grade 7) 23 35.9% 
 Secondary school (grade 8-12) 37 57.8% 
Tertiary (higher than grade12) 4 6.3% 
Total 64 100% 
 
Of the ninety cases (86.5%) for which a psychiatric diagnosis was recorded in the ACT service folder, 
fifty (55.6%) patients had schizophrenia, twenty-eight (31.1%) had schizoaffective disorder and 
twelve (13.3%) had any form of bipolar disorder (see table 3). The remaining fourteen cases had a 
psychiatric diagnosis of SMI which was not recorded in the inpatient hospital folder, Clinicom 
records or the ACT folder for the study period and data collection.  The rates of occurrence of the 
three psychiatric conditions in females and males were significantly different in all three psychiatric 
conditions (Chi-square=13.821, df=2, p=0.001). A significantly larger proportion of males compared 
to females had a diagnosis of schizophrenia (66.7% versus 33.3%) whilst a larger proportion of 
females compared to males had a diagnosis of bipolar disorder (30% versus 5%) and schizoaffective 
disorder (37.7% versus 28.3%), (see Table 3). 
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Ninety-one (n=91) out of 104 cases have used substances. (see Table 4). Of the cases for which 
substance use is known, for males and females combined, forty (44%) of the patients used cannabis, 
thirty (33%) used methamphetamine and nine (10.5%) used other substances including 
methaqualone (mandrax) and glue. Of the 92 patients (88.5%) that were reported to use alcohol, 21 
(22.8%) had an alcohol use disorder. Sixty-five cases smoked tobacco of which sixty patients (92.3%) 
smoked currently.  Five of the sample (7.7%) were documented as never having smoked tobacco.  
When males were compared to females, there was significantly higher number of males who used 
substances compared to females with regards to cannabis (Chi-Square 23.96, df=1, p=0.000) and 
methamphetamine (Chi-Square=4.51, df=1, p=0.038).There was no significant gender difference in 
use of other substances, including alcohol and tobacco.   
 
Table 4: Substance use within the ACT population categorised by gender.  
 
 
Substance used 
 
Females (F) 
 
 
Males (M) 
Chi-
square 
p value  
 Denominator = 
number of 
patients for 
whom  data was 
available 
Percentage 
within 
gender 
Denominator = 
number of 
patients with 
data   
Percentage 
within 
gender 
 
Table 3: Gender of patients and psychiatric diagnosis of severe mental illness (SMI) (n=90)     
                                   
 
   Total for 
all SMI  
conditions  Schizophrenia 
 Schizoaffective 
disorder Bipolar disorder 
Gender F  Count n=10 n=11 n=9 n=30 
Percentage  within 
gender 
33.3% 36.7% 30.0%  
M  Count n=40 n=17 n=3 n=60 
Percentage  within 
gender 
66.7% 28.3% 5.0%  
Total count Count n=50 n=28 n=12 n=90 
Percentage of total 
group(n=90) 
55.6% 31.1% 13.3%  
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Cannabis 3/32 
 
9.4% 37/59 
 
62.7% 0.000 
Methamphetamine 6/32 
 
18.8% 24/59 40.7% 0.038 
*other substances  1/31 
 
3.2% 8/55 
 
14.5% 0.147 
Alcohol 5/32 
 
15.6% 
 
16/60 
 
26.7% 0.301 
Tobacco smoking 21/24 
 
87.5% 
 
39/41 
 
95.1% 0.350 
*other substances: methaqualone, glue 
 
 
Ninety-nine (95.2%) patients were prescribed psychotropic drugs which included typical and atypical 
antipsychotics, mood stabilisers and antidepressants.  Seventy eight patients (78.8%) were 
prescribed typical antipsychotics, seventy eight patients (78.8%) were prescribed long acting 
injectable antipsychotics and fifty-nine patients (59.6%) were prescribed atypical antipsychotics. Of 
those prescribed typical antipsychotics, thirty (38.5%) had a metabolic screen recorded over the 
study period and twenty-eight patients (47.5%) prescribed atypical antipsychotics had a metabolic 
screen. Thus, in total 58 patients (36.5%) in the study had a metabolic screen recorded. The majority 
of patients (ninety-nine or 95.2%)  were prescribed more than one type of antipsychotic medication, 
for example a long acting injectable antipsychotic and an oral agent. The combined number of 
patients screened for common medical conditions at the community clinics and Valkenberg Hospital 
was 39 (37.5%). 
 
Table 5: Documentation of medical conditions at Valkenberg Hospital and Community Health 
Centres combined. 
 
Medical condition Responses by gender Total number 
documented 
(males and 
females) 
Percentage 
of total 
sample 
Percentage 
of all cases 
with a 
medical 
condition 
 male female    
Medication side-
effects 
14 7 21 22.3% 39.6% 
Hypercholesterolemia 9 8 17 18.1% 32.1% 
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Hypertension  2 8 10 10.6% 18.9% 
HIV 3 5 8 8.5% 15.1% 
Diabetes mellitus  2 3 5 5.3% 9.4% 
Chronic obstructive 
pulmonary disease 
(COPD) 
3 1 4 4.3% 7.5% 
Gastro-oesophageal 
reflux disease (GORD) 
4 0 4 4.3% 7.5% 
Asthma 1 2 3 3.2% 5.7% 
Eye conditions 2 1 3 3.2% 5.7% 
Skin conditions 0 3 3 3.2% 5.7% 
Dental  caries 2 0 2 2.1% 3.8% 
Arthritis 0 2 2 2.1% 3.8% 
Thyroid conditions  0 2 2 2.1% 3.8% 
Hepatitis 1 1 2 2.1% 3.8% 
Obesity 0 2 2 2.1% 3.8% 
Anaemia 0 2 2 2.1% 3.8% 
Epilepsy 1 0 1 1.1% 1.9% 
Renal conditions 1 0 1 1.1% 1.9% 
Hearing problems 0 1 1 1.1% 1.9% 
Total  45 49 94 100%  
 
 
 
Table 6: Medical conditions documented at Valkenberg Hospital and the Community Clinics 
 
Medical condition Responses at VBH Responses at CHC 
 Count Percentage of 
VBH responses 
Count Percentage of 
CHC responses 
Hypertension 8 9.5% 5 17.2% 
Diabetes mellitus 5 6.0% 3 10.3% 
Hypercholesterolemia 15 17.9% 7 24.1% 
HIV 8 9.5% 3 10.3% 
Chronic obstructive 
pulmonary disease 
(COPD) 
2 2.4% 3 10.3% 
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Epilepsy 1 1.2% 1 3.4% 
Asthma 3 3.6% 2 6.9% 
Medication side effects 21 25.0% 0 0% 
Dental caries 2 2.4% 0 0% 
Skin conditions 2 2.4% 1 3.4% 
Arthritis 1 1.2% 1 3.4% 
Thyroid conditions  2 2.4% 0 0% 
Hepatitis  2 2.4% 0 0% 
Eye conditions 3 3.6% 0 0% 
Gastroesophageal reflux 
disease (GORD) 
4 4.8% 1 3.4% 
Obesity 2 2.4% 0 0% 
Anaemia  2 2.4% 0 0% 
Renal conditions 1 1.2% 0 0% 
Cardiac conditions 0 0% 1 3.4% 
Hearing problems 0 0% 1 3.4% 
 
Of the data that was available in either the VBH ACT service or CHC folders, the following rates of 
medical conditions were observed (see Tables 5 and 6). For a majority of patients, as detailed below, 
no data was available in the folders to indicate whether specific medical conditions were screened 
for or excluded. Of the entire study sample fifty-three patients (51%) had at least one medical 
condition and fifty-one (49%) had no medical conditions recorded. The frequency of medical 
conditions per patient is presented in Table 7. The most common active medical conditions 
combined at the 2 facilities were medication side-effects which includes extrapyramidal side-effects, 
drooling, clozapine induced constipation (22.3%), hypercholesterolemia (18.1%) and hypertension 
(10.6%). A greater number of medical conditions were recorded at Valkenberg hospital compared to 
the community clinics (Table 6). At Valkenberg hospital the most common medical conditions were 
medication side-effects (25%), hypercholesterolemia (17.9%) and hypertension (9.5%) (see Table 6). 
At the CHCs the commonest conditions documented were hypercholesterolemia (24.1%), 
hypertension (17.2%) and HIV, diabetes mellitus and COPD at 10.3% (see Table 6). 
 
 
Table 7: Frequency of medical conditions per patient at VBH and CHC combined (n=104)  
 
  Number of   diseases  
           
Frequency     Percentage 
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 0 51 49.0% 
 1 29 27.9% 
 2 12 11.5% 
 3 8 7.7% 
 4 3 2.9% 
 5 1 1.0% 
 
Total 104 100.0 
 
The highest numbers of patients with metabolic illnesses such as hypertension, diabetes mellitus and 
hypercholesterolemia occurred in the age range of 44-53 years. Hypertension, diabetes mellitus and 
HIV were more common in females compared to males in this population (see Table 8). Of the 
medical conditions documented, only hypertension was significantly correlated with SMI  (Chi-
square Linear-by-Linear association=5.09, df=1, p=0.024). There were no other statistically significant 
correlations of any severe mental illness with any other medical condition documented.  
 
There were also no significant differences between the rates of follow up at the clinic and the 
documented psychiatric conditions. 
 
Discussion 
This study set out to determine the rate and type of medical conditions among patients treated by 
the ACT team of Valkenberg hospital and to compare that to the medical conditions recorded at the 
community health centres. 
 
The study found low rates of documented medical conditions among the patients with SMI managed 
by the Assertive community treatment team of Valkenberg hospital and the community clinics. 
These findings are not consistent with other studies that found high rates of chronic medical 
conditions and metabolic syndrome among people with severe mental illness (14, 18, 28, 29). The 
rate of other medical conditions is likely to be underestimated as patients were not routinely 
screened at both Valkenberg hospital and the community health centres. Similar findings have also 
been reported found in other studies (12, 14). Possible barriers to screening have been captured in a 
study by Wheeler et al and includes lack of practitioner knowledge and skills, lack of clarity about 
whose role it is to do the screening, poor liaison between primary care and ACT service, clients’ poor 
socioeconomic status influencing their ability to access the clinics and lack of time and resources to 
do the screening (5).  
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The high rates of hypercholesterolemia and hypertension that were found among the patients at 
Valkenberg hospital could be related to multiple factors including the side-effect profile of the 
psychotropic drugs, high rates of smoking, poor diet and lack of exercise (4).  This alerts to the high 
risk for these patients of cardiovascular disease. Ceiley et al conducted a study looking at active 
medical conditions on an ACT team and found that hypertension was the second most common 
condition after osteoarthritis but hyperlipidemia was less common in their study (18). 
 
Several common health conditions, such as oral health and visual problems, are not consistently or 
routinely screened for or recorded in the general health services studied and this deficit was 
reflected in the study findings.  
 
No deaths were recorded for this study period. 
 
This study results also demonstrate a significant discrepancy between the number of patients 
recorded to have a medical condition at the hospital and community clinic health facilities, especially 
for the metabolic conditions and HIV.  Of concern, it appears some medical conditions were 
recorded at Valkenberg hospital and not the community clinic where the clients are expected to 
receive treatment for these conditions. This was the case for hypertension, diabetes mellitus and 
HIV which are illnesses known to lead to significant morbidity and mortality if left untreated. This 
finding could indicate that medical conditions were diagnosed at Valkenberg hospital but that 
patients did not necessarily follow through with the referral to the clinic for further management. 
 
Another key finding was that medication side-effects were recorded at Valkenberg hospital and 
none at the local clinics. This could imply that mental health care workers are more aware of 
medication induced side-effects and has implications for the community based care of patients on 
such medications.   
 
This study highlights low levels of screening for metabolic conditions at both Valkenberg hospital and 
the community health clinics. This has been found in the literature both nationally and 
internationally (7, 12, 14). A study by Saloojee, et al found that less than one percent of patients 
with severe mental illness in that study population was screened for all five components of 
metabolic syndrome (12).  Cardiometabolic monitoring of patients treated with antipsychotic 
medications  are generally low despite the United States of America Federal Food and Drug 
Association class warning about the cardiometabolic side effects of second generation agents (30) 
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and the known increase in risks of cardiometabolic side effects with combinations of antipsychotics 
(19).  
The median age for patients in the ACT team was 50 years for males and 42 years for males. There 
was a clustering of increased metabolic illnesses in the age range of 44-53 years.  A study of 
metabolic syndrome in people with SMI showed that the prevalence of metabolic syndrome 
increased in the age groups from 30 to 59 years old (31). Based on this observation it is apparent 
that the Valkenberg Hospital ACT population is not only burdened with SMI but also at greater risk of 
having a medical condition based on age. The ACT team does not provide for the management of 
patients older than 60 years who are likely to have numerous comorbid medical conditions. Based 
on the evidence that mental health care users generally access and receive less optimal medical care 
than the general population, the health status of the patients over 60 years old who have been 
discharged from the ACT service is of concern.  
 
Significantly high rate of smoking and substance use disorders were found in this study population. 
This is consistent with high rates of substance use in the Western Cape (32-34). Cannabis and 
methamphetamine use was higher in males compared to females. A previous South African study 
found that males were eight to nine times more likely than females to use any substance(35).  This 
has implications for adherence to treatment as well as morbidity, mortality, recurrent relapses and 
hospital admissions, unemployment and poor psychosocial functioning in the population with SMI.  
One can argue that the ACT team should consider providing a substance use disorders clinical service 
or routinely provide motivational interviewing with the clients to assist them to manage their 
substance use. A significant number of patients admitted their substance use to the ACT staff which 
could be seen as a positive clinician-patient relationship and should be used to target substance use 
amongst the patients. Brief screening for substance use disorders should also be undertaken at 
primary health care level. 
 
Based on the study findings, the following recommendations are made for the Valkenberg Hospital 
ACT service as well as primary health care service:  
 
First, the responsibility for regular metabolic, HIV and other health related screening on the ACT 
clients need to be determined.  Routine metabolic screening however is the responsibility of the 
prescribing clinician and in this instance it is recommended that the ACT team provide this service. 
The ACT team is best placed to screen for medical conditions as the staff have regular contact with 
clients and can liaise with treatment support partner and CHC. Ideally the ACT staff members need 
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to work closely with the patients and community health centre staff to ensure that this screening is 
done.  
 
The ACT team needs to be clear on what needs to be screened for and how frequently screening 
should be done therefore they need to be up to date with the most recent screening protocols 
appropriate to their setting. 
 
Screening should not only focus on metabolic illness but all illnesses common to this group including 
eye and dental health care. 
 
Second, the ACT team should be more involved in health promotion and prevention of chronic 
illness. They should address physical health care needs in a preventive rather than reactive manner. 
This includes psychoeducation on regular testing for medical conditions especially HIV and metabolic 
syndrome, smoking cessation and the need for routine gynaecological screening and regular dental 
visits. 
  
Third, a recommendation from the findings is that case management of ACT patients could be re-
viewed to include integrated management of psychiatric disorders, substance use disorders and 
common primary medical conditions as well as health promotion. 
 
Limitations of the study 
 
There were several limitations to this study.  
The data and interpretation of the data in the study were dependent on the extent to which clinical 
notes were recorded in the patient folders.   Thus missing data in this study may have influenced the 
results of the study.  Obtaining the clinic data for the ACT clients was challenging as some folders 
were lost.  Further, consent was not granted by all the community clinics that the ACT clients attend 
resulting in incomplete data for approximately seventeen patients attending those clinics.  
The data extraction was undertaken by the primary researcher. 
 
The sampling strategy used in this study was convenience sampling which may have influenced 
outcomes of the study. 
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The study was located in one geographical area and findings will not be generalizable to other 
service settings. 
The study sample was small and the study period was relatively short which may be a limitation for 
generalization of the study results. 
The strength of the study is that it highlights that clients with SMI do not receive adequate care in 
the community. It highlights a service gap and service delivery need which has to be addressed in 
future. 
Conclusion 
The study highlights that the documentation and screening of medical conditions by the ACT team 
and CHC is suboptimal. . Medical conditions are poorly screened for and therefor may go untreated 
in this population.  
Treating clinicians should be clear on what screening is required and whose role it is to undertake 
this screening.  
The ACT service has proven itself to be successful in reducing recurrent hospital admissions in 
patients with severe mental illness but does not address their comorbid medical conditions which 
affect quality of life and life expectancy. 
The ACT team is in the better position to provide the screening and management of common 
medical conditions.  
In conclusion, further research is needed in physical health outcomes in patients with severe mental 
illness in resource limited settings.  Future research could also focus on the management of 
comorbid medical conditions among patients with SMI and the specific roles of mental health and 
general health practitioners in the care of this vulnerable population.   
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RESEARCH QUESTIONNAIRE 
Common active comorbid medical conditions among mental health users treated by the Assertive 
Community Treatment team at Valkenberg psychiatric hospital 
DEMOGRAPHIC AND CLINICAL INFORMATION 
DATE: 
1. IDENTIFYING DATA: 
 
 
 
 
2. MARITAL STATUS: 
1=SINGLE, 2=MARRIED, 3=DIVORCED/SEPARATED, 3=WIDOW/WIDOWER 
3. HLOE: 
A. PRIMARY SCHOOL  (less than grade 7) 
B. SECONDARY SCHOOL (grade 8-12) 
C. TERTIARY EDUCATION (higher than grade 12) 
D. NOT RECORDED 
 
4. EMPLOYMENT IN LAST YEAR : YES/NO AND TYPE:___________ 
A. UNEMPLOYED 
B. PART TIME EMPLOYMENT 
C. FULL TIME EMPLOYMENT 
D. NOT RECORDED 
 
5. DISABLITY GRANT: 
A. YES 
B. NO 
C. NOT RECORDED 
 
6. DATE WHEN ENROLLED IN ACT PROGRAM:____________  
 
7. PRIMARY PSYCHIATRIC DIAGNOSIS 
 
A. SCHIZOPHRENIA 
B. SCHIZOAFFECTIVE DISORDER 
C. BIPOLAR DISORDER 
D. OTHER – specify:  _______________________________________________ 
PATIENT LABEL 
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8. COMORMID SUBTANCE USE AND WHICH SUBSTANCE 
A. ALCOHOL 
B. CANNABIS 
C. METHAMPHETAMINE (TIK) 
D. OTHER – specify: ________________________________________________ 
E. COMBINATION OF ABOVE 
F. NONE OF ABOVE 
 
9. SMOKER 
A. CURRENT SMOKER: YES/NO 
B. EX-SMOKER: YES/NO 
C. NEVER SMOKED 
D. NOT RECORDED
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10. PSYCHOTROPIC MEDICATION DURING 01/01/2015-31/12/2015 : 
 VALKENBERG HOSPITAL FOLDER COMMUNITY HEALTH CLINIC 
FOLDER 
TYPICAL ANTIPSYCHOTICS  
YES/NO 
SPECIFY WHICH ONES 
 
  
  
  
  
  
  
ATYPICAL 
ANTIPSYCHOTICS  
YES/NO 
SPECIFY WHICH ONES 
  
  
  
  
  
  
MOOD STABILISERS/ 
ANTIDEPRESSANTS 
YES/NO 
SPECIFY WHICH ONES 
  
  
  
  
  
  
ANTICHOLINERGICS 
YES/NO 
SPECIFY WHICH ONES 
  
  
  
  
  
  
OTHER PSYCHOTROPIC 
MEDICATION(stimulants, 
etc): 
YES/NO 
SPECIFY WHICH ONES 
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11. Investigations during 2015  
        Facility:   VBH  /  CHC 
Investigatio
ns of 
interest at 
VBH 
Ever 
done at 
VBH 
during 
the year? 
Result  Investiga
tions of 
interest 
at CHC 
Ever 
done at 
CHC 
during 
the 
year? 
Result 
WEIGHT 
(KG) 
 
 
No  /  Yes  
→ 
# times: 
_____ 
_____.__ 
kg 
 WEIGHT 
(KG) 
 
 
No  /  
Yes  → 
# times: 
_____ 
_____._
_ kg 
HEIGHT 
(CM) 
 
 
No  /  Yes  
→ 
# times: 
_____ 
______c
m 
 HEIGHT 
(CM) 
 
 
No  /  
Yes  → 
# times: 
_____ 
______c
m 
BODY 
MASS 
INDEX 
 
No  /  Yes  
→ 
# times: 
_____ 
  BODY 
MASS 
INDEX 
 
No  /  
Yes  → 
# times: 
_____ 
 
BLOOD 
PRESSURE 
 
No  /  Yes  
→ 
# times: 
_____ 
  BLOOD 
PRESSUR
E 
 
No  /  
Yes  → 
# times: 
_____ 
 
BLOOD 
GLUCOSE 
 
No  /  Yes  
→ 
# times: 
_____ 
  BLOOD 
GLUCOS
E 
 
No  /  
Yes  → 
# times: 
_____ 
 
CHOLESTER
OL 
 
No  /  Yes  
→ 
# times: 
_____ 
  CHOLEST
EROL 
No  /  
Yes  → 
# times: 
_____ 
 
TRIGLYCERI
DES 
 
 
No  /  Yes  
→ 
# times: 
_____ 
  TRIGLYC
ERIDES 
 
No  /  
Yes  → 
# times: 
_____ 
 
HIV 
 
 
No  /  Yes  
→ 
# times: 
_____ 
neg.  /  
pos.  → 
 HIV 
 
No  /  
Yes  → 
# times: 
_____ 
neg.  /  
pos.  → 
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12. CO-MORBID MEDICAL CONDITIONS PRESENT AS DOCUMENTED IN 2015                                         
DATE OF FOLDER REVIEW:______________--- 
PLEASE FILL IN THIS PAGE FOR BOTH VBH AND CHC                                                                                    
Facility:   VBH  /  CHC 
Co-morbidities of interest Existing 
diagnosis, 
documented 
in notes 
NEW 
Diagnosis 
made 
Referral made 
HYPERTENSION  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
DIABETES MELLITUS  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
HYPERCHOLESTEROLAEMIA  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
HIV No  /  Yes  
→ 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
______________ 
 
COPD 
 
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
EPILEPSY  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
ASTHMA  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
OTHER (e.g. Epilepsy, dental problems, 
movement disorders, chronic headaches, eye 
problems) 
Specify: 
______________________________________ 
 
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
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13. CO-MORBID MEDICAL CONDITIONS PRESENT AS DOCUMENTED IN 2015                                         
DATE OF FOLDER REVIEW:______________--- 
PLEASE FILL IN THIS PAGE FOR BOTH VBH AND CHC                                                                                    
Facility:   VBH  /  CHC 
Co-morbidities of interest Existing 
diagnosis, 
documented 
in notes 
NEW 
Diagnosis 
made 
Referral made 
HYPERTENSION  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
DIABETES MELLITUS  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
HYPERCHOLESTEROLAEMIA  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
HIV No  /  Yes  
→ 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
______________ 
 
COPD 
 
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
EPILEPSY  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
ASTHMA  
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
OTHER (e.g. Epilepsy, dental problems, 
movement disorders, chronic headaches, eye 
problems) 
Specify: 
______________________________________ 
 
No  /  Yes  
→ 
 
No  /  Yes  
→ 
No  /  Yes  → 
CHC name: 
_______________ 
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General article format/layout 
Accepted manuscripts not in the correct format specified in these guidelines will be returned to the author(s) for 
correction, which will delay publication. 
  
General: 
• Manuscripts must be written in UK English. 
• The manuscript must be in Microsoft Word or RTF document format. Text must be single-spaced, in 
12-point Times New Roman font, and contain no unnecessary formatting (such as text in boxes). 
• Please make your article concise, even if it is below the word limit. 
• Qualifications, full affiliation (department, school/faculty, institution, city, country) and contact details 
of ALL authors must be provided in the manuscript, and in the online submission process. 
• Abbreviations should be spelt out when first used and thereafter used consistently, e.g. ‘intravenous 
(IV)’ or ‘Department of Health (DoH)’. 
• Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dL). 
• Litres is denoted with an uppercase L e.g. ‘mL’ for millilitres). 
• Units should be preceded by a space (except for % and ºC), e.g. ’40 kg’ and ’20 cm’ but ‘50%’ and 
’19ºC’. 
• Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not B for beta, etc. 
• Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The respondent stated: ‘…’ 
• Round brackets (parentheses) should be used, as opposed to square brackets, which are reserved for 
denoting concentrations or insertions in direct quotes. 
• If you wish material to be in a box, simply indicate this in the text. You may use the table format –this 
is the only exception Please DO NOT use fill, format lines and so on. 
Research 
Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original research study. The 
article should contain the following sections: introduction, methods, results, discussion and conclusion, and 
should include a structured abstract (see below). The introduction should be concise – no more than three 
paragraphs – on the background to the research question, and must include references to other relevant 
published studies that clearly lay out the rationale for conducting the study. Some common reasons for 
conducting a study are: to fill a gap in the literature, a logical extension of previous work, or to answer an 
important clinical question. If other papers related to the same study have been published previously, please 
make sure to refer to them specifically. Describe the study methods in as much detail as possible so that others 
would be able to replicate the study should they need to. Results should describe the study sample as well as the 
findings from the study itself, but all interpretation of findings must be kept in the discussion section, which 
should consider primary outcomes first before any secondary or tertiary findings or post-hoc analyses. The 
conclusion should briefly summarise the main message of the paper and provide recommendations for further 
study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that provided added 
value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text 
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Structured abstract 
• This should be 250-400 words, with the following recommended headings:  
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to establish 
o Methods: must include study design, number of participants, description of the intervention, 
primary and secondary outcomes, any specific analyses that were done on the data. 
o Results: first sentence must be brief population and sample description; outline the results 
according to the methods described. Primary outcomes must be described first, even if they 
are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has been approved by all 
authors. 
• Do not include any references in the abstracts. 
  
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, Results, Discussion, 
Conclusions. 
The following are additional heading or section options that may appear within these: 
• Objectives (within Introduction/Background): a clear statement of the main aim of the study and the 
major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation, blinding, placebo 
control, case control, crossover, criterion standards for diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of participating centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering and completing the 
study, sex, age and any other biological, behavioural, social or cultural factors (e.g. smoking status, 
socioeconomic group, educational attainment, co-existing disease indicators, etc) that may have an 
impact on the study results. Clearly define how participants were enrolled, and describe selection and 
exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long? Typically for randomised 
controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and those ultimately 
measured. Explain differences, if any. 
  
Results 
• Start with description of the population and sample. Include key characteristics of comparison groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, the exact 
level of statistical significance and the number need to treat/harm. Whenever possible, state absolute 
rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. Our house style is to present this as 
follows: 
• g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean (SD). 
• Leave interpretation to the Discussion section. The Results section should just report the findings as per 
the Methods section. 
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Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 
• Strengths and weaknesses in relation to other studies 
• The meaning of the study – e.g. what this study means to clinicians and policymakers 
• Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary conclusions and their 
implications, suggesting areas for further research if appropriate. Do not go beyond the data in the article. 
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